GH/IGF-I and bone resorption in vivo and in vitro
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
IGF-I may act as one of several coupling agents by activating bone formation and bone resorption.In vivo studies in normal subjects, postmenopausal women and patients with excess or diminished GH production (acromegaly and GHD) indicate that both GH and IGF-I activate osteoclasts, but that GH has a more pronounced effect, independently of IGF-I.In vitro, GH and IGF receptors have been demonstrated on osteoclasts and both GH and IGF-I may directly modify osteoclast function and activity. In addition to direct effects on osteoclasts, GH and IGF-I may affect bone resorption indirectly by stimulating release of paracrine mediators that regulate osteoclastic resorption (cytokines). Critical for the bone resorptive process is the balance between OPG and RANKL, which is regulated by many systemic factors.In vivo and in vitro,GH/IGF-I may modulate this balance but these studies are difficult to interpret, reflecting the complexity of this system. Increased OPG expression may possibly protect against GH/IGF-I-induced bone resorption and potentially be important for the long-term beneficial effects of GH replacement. Further studies investigating the OPG/RANKL ratio and system in experimental and transgenic GH/IGF models may clarify these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · cited 1×
“The final piece in the system is the receptor for RANKL, which previously was identified on immune cells and named RANK ( 56 ).”
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“Finally, based on the known effects estrogen has on OPG protein and gene expression in vivo and in vitro (67, 68 ), the effects of estrogen replacement therapy may mask effects of GH/IGF on circulating OPG and explain the unchanged levels in some treatment studies.”
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513 · cited 1×
“Furthermore, experimental models show that enhanced T cell production of TNF resulting from increased T cell number in the bone marrow is necessary for the increase in osteoclast and the bone wasting induced by ovariectomy (42, 43 ).”
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
Bord, S., Ireland, D. C., Beavan, S. R., & Compston, J. E. (2003) · Bone · doi:10.1016/s8756-3282(02)00953-5 · Cited by 333 · cited 1×
“Finally, based on the known effects estrogen has on OPG protein and gene expression in vivo and in vitro ( 67 , 68), the effects of estrogen replacement therapy may mask effects of GH/IGF on circulating OPG and explain the unchanged levels in some treatment studies.”
Wüster, C., Abs, R., Bengtsson, B.-Å., Bennmarker, H., Feldt-Rasmussen, U., Hernberg-Ståhl, E., Monson, J. P., Westberg, B., & Wilton, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.398 · Cited by 267
Cited by
De Benedetti, F., Rucci, N., Del Fattore, A., Peruzzi, B., Paro, R., Longo, M., Vivarelli, M., Muratori, F., Berni, S., Ballanti, P., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22175 · Cited by 296
Prisby, R. D., Lafage-Proust, M.-H., Malaval, L., Belli, A., & Vico, L. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.07.004 · Cited by 240
“Endogenous growth hormone is critical for the maintenance of bone mass in adults (Ueland, 2005) and aged individuals experience declines in circulating growth hormone levels (Sherlock and Toogood, 2007).”
BackgroundMazziotti, G., Bianchi, A., Bonadonna, S., Nuzzo, M., Cimino, V., Fusco, A., De Marinis, L., & Giustina, A. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060112 · Cited by 141
“GH stimulates the proliferation of osteoblasts and, to some extent, it also stimulates differentiated functions of these cells.((1,28)) Moreover, GH FIG.”
BackgroundBone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
“IGF also promotes the RANKL production in OBs to regulate OCs [37].”
Background
Metadata
- Authors
- Ueland, T.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03
- Volume
- 152
- Issue
- 3
- Pages
- 327-332
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2096842658
- Cited by
- 88
- References
- 7
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GH/IGF-I and bone resorption in vivo and in vitro. https://app.cochat.ai/papers/10.1530/eje.1.01874
- The paper
- Ueland, T. (2005). GH/IGF-I and bone resorption in vivo and in vitro. European Journal of Endocrinology. https://doi.org/10.1530/eje.1.01874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.